Voronoi, Inc. (310210.KQ) researches, develops, and commercializes small molecule kinase inhibitors and targeted protein degraders for oncology and immunology indications; its pipeline features VRN01, an oral leucine-rich repeat kinase 2 inhibitor for glioblastoma multiforme and pancreatic cancers; VRN07, VRN06, and VRN11, third-generation EGFR inhibitors for non-small cell lung cancer including EGFR C797S mutations and brain metastases; VRN08 and VRN10 for breast and HER2-positive solid tumors; VRN02 for rheumatoid arthritis and atopic dermatitis; VRN04-1 for autoimmune diseases; VRN04-2 for multiple sclerosis and amyotrophic lateral sclerosis; VRN13 for pulmonary arterial hypertension; and VRN14 for refractory solid cancers. The company leverages its proprietary VORONOMICS platform, integrating AI-driven drug discovery, in-vitro, in-vivo testing across six labs in three research centers, and high-throughput screening of over 550,000 compounds annually to accelerate candidate development from over 4.5 years to under one year. Founded in 2015 and headquartered in Incheon, South Korea, with an additional hub in Boston, Massachusetts, Voronoi operates primarily in South Korea and the United States, focusing on technology transfer of pre-clinical candidates and AI-based drug development platforms. In recent developments, Voronoi secured first-place ranking in small molecule drug patents under the Patent Cooperation Treaty in March 2025; announced positive early clinical efficacy data for VRN11 in low-dose treatment of EGFR C797S mutant non-small cell lung cancer at AACR 2025 in April; and received domestic Phase 1 IND approval for VRN10 targeting HER2-positive solid tumors from South Korea's Ministry of Food and Drug Safety in March 2025; the company also participates in the AACR-NCI-EORTC International Conference in Boston from October 22-26, 2025.